[Eosphagomanometric finding in man after intravenous administration of a new cholinolytic (pramiverine), atropine and scopolamine butylbromide].
The tone depressing effect on deglutition peristaltic processes in the esophagus by i.v. application of 4,4-diphenyl-N-isopropyl-cyclohexylamine hydrochloride (pramiverine, Sistalgin) (0.03 and 0.045 mg/kg body weight), atropine (0.5 mg) and hyoscine-N-butylbromide (scopolamine-butylbromide, SBB) (20 mg) was tested on trained subjects. During the first 30 min following the larger dose of pramiverine, the effect is not quite so pronounced as it is seen after the usual atropine dose; from the 30th to the 60th min, however, the tone depressing effect of pramiverine is superior to that of atropine, 1 h after application of pyramiverine the pressure amplitude is still reduced to 54.3% of the initial value, while after atropine the effect has returned to 70.9% of the initial value by this time. Neither atropine nor pramiverine were able to exert a tone depressing effect as pronounced as that of SSB. But 30 min after application of the  effect of SBB was not statistically significant any longer and after 40 min it could not be measured at all. Following atropine and SBB, the side effect of tachycardia was correlated exactly to the main effect tested. Further side effects, such as dryness of mouth and disturbed accomodation, were most pronounced after atropine. With pramiverine at the effective doses of 0.03 and 0.045 mg/kg, the side effects were not appreciable; neither objective measuring nor subjective reports of the subjects indicated any conspicuous deviations.
D001285:Atropine / Q000494:pharmacology*; D001559:Benzhydryl Compounds / Q000494:pharmacology; D002086:Butylscopolammonium Bromide / Q000494:pharmacology*; D003514:Cyclohexylamines / Q000494:pharmacology*; D003679:Deglutition / Q000187:drug effects; D004947:Esophagus / Q000187:drug effects*; D006801:Humans; D009129:Muscle Tonus / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D010276:Parasympatholytics / Q000494:pharmacology*; D011312:Pressure; D012602:Scopolamine Derivatives
D001559:Benzhydryl Compounds; D003514:Cyclohexylamines; D010276:Parasympatholytics; D012602:Scopolamine Derivatives; D002086:Butylscopolammonium Bromide; D001285:Atropine
Oesophagusmanometrische Befunde beim Menschen nach intravenöser Applikation eines neuen Cholinolytikums (Pramiverin), von Atropin und von Scopolamin-butylbromid